[The bioregulatory therapy of patients with chronic pyelonephritis].
Prostatilen (5 mg/day i.m. for 5 days) was given to 46 patients with chronic pyelonephritis in the latent inflammation phase. The treatment resulted in relief of clinical symptoms, positive trend in laboratory indices characterizing activity of renal inflammation, albumin-globulin ratio. There was a decrease in leukocyturia, bacteriuria, ESR, blood fibrinogen and ceruloplasmin levels. Prostatilen reduced hypercoagulation and enhanced fibrinolytic activity of blood. The immunograms showed prostatilen-induced correction of immunity: T-lymphocyte count and functional activity increased, proportion of T-cell subpopulations returned to normal, metabolic activity of phagocyte oxygen-dependent substances became more intensive. The ability of prostatilen to initiate normalization of hemocoagulation and immunity is thought to be an essential factor of its therapeutic efficacy in chronic pyelonephritis.
al-Shukri
S Kh
SKh
Gorbachev
A G
AG
Kuz'min
I V
IV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D010455:Peptides / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D010455:Peptides; C069549:prostatilen